Genetics are key to hormone therapy lowering risk of broken bones in older women
University at Buffalo Health and Medicine News May 03, 2017
Women at the highest genetic risk for fracture benefit the most from hormone therapy, according to a first–of–its–kind study led by researchers at the University at Buffalo.
The study included nearly 10,000 participants from the WomenÂs Health Initiative (WHI), a national, long–term study of more than 150,000 women.
ÂWe found that women who are genetically at the highest fracture risk can enjoy the greatest protection from fracture when they use hormone therapy, said Heather Ochs–Balcom, associate professor of epidemiology and environmental health in UBÂs School of Public Health and Health Professions, who led the research team.
The findings were published online ahead of print in the Journal of Clinical Endocrinology and Metabolism. The paperÂs first author, Youjin Wang, conducted the research as a doctoral candidate in epidemiology and environmental health at UB.
ÂThis study provides a better understanding of who can benefit the most in terms of bone health from hormone therapy use, Ochs–Balcom said, adding that the results have implications for personalized medicine. ÂItÂs important information as women and their doctors make decisions about hormone therapy use.Â
The study, believed to be the first to investigate gene–hormone therapy interaction on fracture in postmenopausal white women, utilizes the largest set of known genes linked to fracture risk from a meta–analysis of genome–wide association studies.
Researchers looked at a subset of 9,922 women from among the more than 27,000 who had participated in WHI hormone therapy clinical trials. They wondered whether women who are more genetically susceptible to fractures could benefit from hormone therapy.
ÂThis is important because, as previous WHI studies have identified, there are risks and benefits with hormone therapy, Ochs–Balcom said. ÂThis is where precision or personalized medicine comes in – the attempt to get the right drugs to the right person to ensure the most benefit and least harm.Â
As women age, their bone mineral density (BMD) decreases, leaving them at greater risk of breaking bones from falling, which also increases as they age. But some women also are more genetically prone to fractures. ÂOur study represents a first look at how inherited predisposition to fracture is related to hormone therapy use, said Ochs–Balcom, who also holds a faculty appointment in the program in Genetics, Genomics and Bioinformatics in UBÂs Jacobs School of Medicine and Biomedical Sciences.
Wang notes that Âfurther studies on gene–therapy interaction are warranted to evaluate the advantages of targeted interventions based on genetic profile. The research team is currently analyzing other gene–environment interactions and recently published another paper on the association of calcium plus vitamin D supplementation and genetic risk of fracture.
Go to Original
The study included nearly 10,000 participants from the WomenÂs Health Initiative (WHI), a national, long–term study of more than 150,000 women.
ÂWe found that women who are genetically at the highest fracture risk can enjoy the greatest protection from fracture when they use hormone therapy, said Heather Ochs–Balcom, associate professor of epidemiology and environmental health in UBÂs School of Public Health and Health Professions, who led the research team.
The findings were published online ahead of print in the Journal of Clinical Endocrinology and Metabolism. The paperÂs first author, Youjin Wang, conducted the research as a doctoral candidate in epidemiology and environmental health at UB.
ÂThis study provides a better understanding of who can benefit the most in terms of bone health from hormone therapy use, Ochs–Balcom said, adding that the results have implications for personalized medicine. ÂItÂs important information as women and their doctors make decisions about hormone therapy use.Â
The study, believed to be the first to investigate gene–hormone therapy interaction on fracture in postmenopausal white women, utilizes the largest set of known genes linked to fracture risk from a meta–analysis of genome–wide association studies.
Researchers looked at a subset of 9,922 women from among the more than 27,000 who had participated in WHI hormone therapy clinical trials. They wondered whether women who are more genetically susceptible to fractures could benefit from hormone therapy.
ÂThis is important because, as previous WHI studies have identified, there are risks and benefits with hormone therapy, Ochs–Balcom said. ÂThis is where precision or personalized medicine comes in – the attempt to get the right drugs to the right person to ensure the most benefit and least harm.Â
As women age, their bone mineral density (BMD) decreases, leaving them at greater risk of breaking bones from falling, which also increases as they age. But some women also are more genetically prone to fractures. ÂOur study represents a first look at how inherited predisposition to fracture is related to hormone therapy use, said Ochs–Balcom, who also holds a faculty appointment in the program in Genetics, Genomics and Bioinformatics in UBÂs Jacobs School of Medicine and Biomedical Sciences.
Wang notes that Âfurther studies on gene–therapy interaction are warranted to evaluate the advantages of targeted interventions based on genetic profile. The research team is currently analyzing other gene–environment interactions and recently published another paper on the association of calcium plus vitamin D supplementation and genetic risk of fracture.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries